Kilitch Drugs (India) Limited — Updates, 12-02-2025: Press Release

Kilitch Drugs Limited reported impressive financial results for Q3 FY25, showcasing a 222% year-on-year increase in consolidated profit after tax (PAT), reaching Rs. 5.61 crore, up from Rs. 1.74 crore in the same quarter last year. Consolidated revenue from operations surged by 77% to Rs. 56.17 crore, compared to Rs. 31.79 crore in Q3 FY24, driven by a sustained global demand for their pharmaceutical products. Standalone results also reflected growth, with PAT increasing by 25% and revenue climbing by 56%, amounting to Rs. 6.88 crore and Rs. 46.51 crore, respectively.

For the nine-month period ending December 2024, net profit rose over 42% year-on-year to Rs. 319.78 crore, while revenue from operations increased by 35%, reaching Rs. 3125.28 crore. Mukund Mehta, Managing Director, emphasized the company’s commitment to sustainable growth and strong returns for stakeholders. With manufacturing facilities certified by various global authorities, Kilitch continues to expand its reach, particularly in key African markets through its innovative and diverse product portfolio. Positive momentum suggests a strong outlook for future performance, making Kilitch a stock to watch closely.